<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50376">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02042729</url>
  </required_header>
  <id_info>
    <org_study_id>E2022-J081-006</org_study_id>
    <nct_id>NCT02042729</nct_id>
  </id_info>
  <brief_title>A Phase 1 Comparative Study of E2022 Current and New Patch Formulations</brief_title>
  <official_title>A Phase 1 Comparative Study of E2022 Current and New Patch Formulations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and pharmacokinetics of new patch
      formulation (tape) of E2022 by conducting patch test.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>10 days (Cohort I) and 40 days (Cohort II)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Adverse Events</measure>
    <time_frame>10 days (Cohort I) and 40 days (Cohort II)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter: Cmax</measure>
    <time_frame>40 days (Cohort II)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter: Tmax</measure>
    <time_frame>40 days (Cohort II)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter: AUC</measure>
    <time_frame>40 days (Cohort II)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>E2022- Tape Formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo E2022</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E2022- New Formulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo E2022- New Formulation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2022- Current Formula Tape</intervention_name>
    <description>Cohort I: E2022 current formula tape administered on a skin application site and evaluated for 10 days during the introductory skin patch test.
Cohort II: E2022 current formula tape administered to skin application site and evaluated for 20 days.</description>
    <arm_group_label>E2022- Tape Formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2022- New Formula Tape</intervention_name>
    <description>Cohort I: E2022 new formula tape administered on a skin application site and evaluated for 10 days during the introductory skin patch test.
Cohort II: E2022 new formula tape administered to skin application site and evaluated for 20 days.</description>
    <arm_group_label>E2022- New Formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2022 Matching Placebo- Current Formula Tape</intervention_name>
    <arm_group_label>Matching Placebo E2022</arm_group_label>
    <other_name>Cohort I: E2022 Matching Placebo current formula tape administered on a skin application site and evaluated for 10 days during the introductory skin patch test.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2022 Matching Placebo- New Formula Tape</intervention_name>
    <arm_group_label>Placebo E2022- New Formulation</arm_group_label>
    <other_name>Cohort I: E2022 Matching Placebo new formula tape administered on a skin application site and evaluated for</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Non-smoker or not smoking for 4 weeks or longer before study treatment

          2. BMI at screening is greater than or equal to 18.5 kg/m2 or less than 25.0 kg/m2

          3. With written informed consent

          4. Given full explanation of this study and is willing to and able to comply with study
             requirements.

        Exclusion criteria

        (Cohort 1 and 2):

          1. Have a disorder which affects the evaluation of study drug such as psychiatric,
             gastrointestinal, hepatic, renal, respiratory, endocrinological, hematological,
             neurological, or cardiovascular system, or congenital metabolic abnormality

          2. Have a clinically significant abnormality or organ dysfunction

          3. Have a history of allergy to drug or food requiring medical treatment or seasonal
             allergy at screening

          4. Have a history or complication of contact dermatitis or atopic dermatitis

          5. Have hairy back or have shaved within 4 weeks before study treatment

          6. Have a skin disease (e.g., eczema, dermatitis, dyschromatosis), or skin damage (e.g.,
             injury, scar, or sun burn) which may affect skin assessment

          7. Have a history or suspected to have drug or alcohol dependence, or positive for urine
             drug screen at baseline or a day before screening

          8. Have had caffeine-containing drink or food, or alcohol within 72 hours before study
             treatment

          9. Have used liquid product (including cosmetics), or applied patch, tape, or bandage on
             the back within 4 weeks before study treatment

         10. Had hard exercise at least 5 days a week or a 1-hour or longer hard exercise within 2
             weeks before study treatment

        (Only Cohort 2):

          1. Meet QTc of greater than 450 milliseconds at screening or immediately before study
             treatment

          2. Had nutrients, herb preparations (e.g. oriental medicine), other food or drink (e.g.,
             grapefruit-containing juice) which may affect the activity of drug-metabolizing
             enzyme or transporter within 2 weeks before study treatment

          3. Had St. John's Wort-containing preparation within 4 weeks before Period 1 application
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hidetaka Hiramatsu</last_name>
    <role>Study Director</role>
    <affiliation>Eisai Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 20, 2014</lastchanged_date>
  <firstreceived_date>January 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>volunteer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
